A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer
Authors:
- 3 August 2013
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 72 (3) , 637-642
Abstract
To compare the efficacy and toxicity of single-agent gemcitabine with gemcitabine plus cisplatin (G + C) in patients with metastatic pancreatic cancer Forty-six patients with metastatic pancreatic cancer were randomized to receive gemcitabine alone (n = 25; 1,000 mg m−2) or G + C (n = 21; 1,000 mg m−2 gemcitabine and 25 mg m−2 cisplatin). Treatments were administered once a week for 3 weeks and repeated every 4 weeks. Patient characteristics were comparable between the gemcitabine alone and G + C groups. The gemcitabine dose intensity was similar between the gemcitabine alone and G + C groups (684 ± 32 vs. 617 ± 31 mg m−2 week−1). The cisplatin dose intensity was 15.1 ± 0.9 mg m−2 week−1 × 9.9 ± 1.8 weeks. Partial response rates were 8 % (2/25) for gemcitabine alone and 4.8 % (1/21) for G + C (p = 1). The median survival and median time to progression were 7.7 and 4.6 months for gemcitabine alone and 7.9 and 3.6 months for G + C, respectively (p = 0.752 and p = 0.857, respectively). Clinical benefit was 36 % for gemcitabine alone and 29 % for G + C (p = 0.592). Quality-adjusted life months were 5.6 ± 0.3 for the gemcitabine alone group and 3.8 ± 0.2 for the G + C group (p < 0.001). The frequency of grade 3/4 neutropenia (8 vs. 19 %) and anemia (8 vs. 10 %) and the number of hospitalization days per month of survival (4.7 ± 1.3 vs. 6.3 ± 1.6 days; p = 0.431) were not significantly different between patients who received gemcitabine alone and those who received G + C. However, patients in the G + C group had a higher rate of thrombocytopenia than did patients in the gemcitabine alone group (62 vs. 24 %; p = 0.009). Gemcitabine alone and G + C had comparable and modest response rates in metastatic pancreatic cancer, but gemcitabine alone produced less toxicities than did G + C.Keywords
This publication has 21 references indexed in Scilit:
- A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinomaJournal of Hematology & Oncology, 2011
- Survival and Prognostic Factors of Unresectable Pancreatic CancerJournal of Clinical Gastroenterology, 2008
- Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic CancerJournal of Clinical Oncology, 2007
- Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic CancerJournal of Clinical Oncology, 2006
- Meta-analysis of inoperable pancreatic cancer: gemcitabine combined with cisplatin versus gemcitabine aloneChinese Journal of Digestive Diseases, 2006
- Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinomaCancer, 2002
- Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenograftsEuropean Journal of Cancer, 1995
- The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexesPharmacology & Therapeutics, 1987